ArticleInflammation and regeneration2026
Effects of intranasal long-acting insulin pretreatment on postoperative delirium and the NLRP3/caspase-1/IL-1β pathway in older patients with esophageal cancer.
Article in Inflammation and regeneration, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInsulin exhibits neuroprotective and anti-inflammatory properties. Preoperative intranasal insulin preconditioning is a potential strategy to prevent postoperative delirium (POD), but prior studies mainly used rapid-acting formulations. This investigation focused on intranasal long-acting insulin, which ensures sustained central nervous system exposure, in elderly patients undergoing radical esophagectomy. We assessed its impact on POD incidence and the NLRP3/caspase-1/IL-1β pathway.
methodsSixty older patients scheduled for elective radical esophagectomy were randomized into two groups. The intervention group (n = 30) received a single intranasal dose of long-acting insulin (30 U) 1 day preoperatively, while the control group (n = 30) received an equivalent volume of physiological saline. POD was evaluated using the Confusion Assessment Method for the ICU on postoperative days 1, 2, and 3. Peripheral blood samples were collected before surgery and postoperatively to measure IL-1β concentrations and NLRP3/caspase-1 mRNA expression in mononuclear cells.
resultsCompared to controls, long-acting insulin pretreatment significantly reduced POD incidence (16.7% vs. 46.7%, P = 0.012) and suppressed the postoperative rise in peripheral IL-1β levels (P < 0.05). In addition, NLRP3 and caspase-1 mRNA expression were notably lower in the insulin group during the postoperative period (P < 0.05). Correlation analysis revealed that in the control group, increases in NLRP3 mRNA, caspase-1 mRNA, and IL-1β levels on postoperative day 1 were significantly associated with the development of POD (P < 0.05). In contrast, no such significant correlations were found in the insulin intervention group.
conclusionPreoperative intranasal long-acting insulin effectively decreases POD incidence in the first 3 days after radical esophagectomy in older patients. This protective effect may be associated with the observed sustained downregulation of the peripheral NLRP3/caspase-1/IL-1β signaling pathway, which consequently weakens the link between early postoperative inflammation and delirium. This emphasizes the advantage of long-acting formulations for continuous neuroprotection during the critical postoperative phase.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.